No Data
hainan huluwa pharmaceutical group (605199.SH): Zhongjia Rui has cumulatively reduced their shareholding by 1.33%.
Hainan Huluwa Pharmaceutical Group (605199.SH) announced on November 27th that on November 26, 2024, the company received a notice from Zhongjiarui regarding the completion of the implementation of the shareholding reduction plan. Zhongjiarui reduced a total of 5,341,050 shares between November 25, 2024 and November 26, 2024, accounting for 1.33% of the company's total share capital.
Here's Why Hainan Huluwa Pharmaceutical Group (SHSE:605199) Has A Meaningful Debt Burden
Hainan Huluwa Pharmaceutical Group (605199.SH): received government subsidies of 10.6863 million yuan
Hainan Huluwa Pharmaceutical Group (605199.SH) announced that the company and its subsidiaries received a total of RMB 10.6863 million in government grants related to revenue from May 31, 2024, to the date of this announcement, unaudited, accounting for 10.03% of the net income attributable to the parent company owner in 2023.
Hainan Huluwa Pharmaceutical Group (605199.SH): Intends to change some of the raised funds investment projects.
Gelonghui November 11th | hainan huluwa pharmaceutical group (605199.SH) announced that the original 'pediatric pharmaceutical research and development' project includes three pharmaceutical research and development sub-projects: children's Ma Long cough and asthma granules, children's Huaji granules, children's pneumonia patches, etc. It is planned to invest 50 million yuan in the funds raised. As of October 31, 2024, a total of 20.1917 million yuan of the raised funds has been used, and the remaining uninvested raised funds balance is 30.5728 million yuan (including interest). Due to factors such as the relatively large difficulty in recruiting children for clinical trials of pediatric medicines, the research and development progress of the above pharmaceutical research and development projects lags behind the previous expectations.
hainan huluwa pharmaceutical group (605199.SH) subsidiary guangxi viwei received pharmaceutical GMP compliance inspection results
Hainan Huluwa Pharmaceutical Group (605199.SH) announced that its wholly-owned subsidiary Guangxi Weiwei Pharmaceutical Co., Ltd. (hereinafter referred to as...
Hainan Huluwa Pharmaceutical Group (605199.SH) obtained the registration certificate for Acalabrutinib injection pharmaceutical.
Hainan Huluwa Pharmaceutical Group (605199.SH) announced that the company recently received approval issued by the National Medical Products Administration regarding...
Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199) Shares May Have Slumped 25% But Getting In Cheap Is Still UnlikelyNo Data
No Data
